Business
DiaMedica Therapeutics Announces Formation of Scientific Advisor Board to Support the Development of DM199 for the Treatment of Preeclampsia
MINNEAPOLIS--(BUSINESS WIRE)-- DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments
About this update from Diamedica Therapeutics Inc.
[{"type":"text","content":" MINNEAPOLIS--(BUSINESS WIRE)--\nDiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, is excited to announce the formation of its Scientific Advisory Board (SAB) to support the development of DM199, its proprietary recombinant serine protease, for the treatment of preeclampsia (PE). The members of the newly formed SAB are renowned experts in PE and maternal-fetal health and will collaborate closely with the company’s leadership to accelerate the development of DM199, for the treatment of preeclampsia.\n\n\n“We are thrilled to welcome these distinguished doctors to our Scientific Advisory Board,” said Rick Pauls, President and Chief Executive Officer of DiaMedica Therapeutics. “Their expertise and guidance will be invaluable as we work to advance treatment options for this potentially fatal and life-threatening condition.”\n\n\nLorianne Masuoka, DiaMedica Therapeutics’ Chief Medical Officer added, “The insights from these experts will be instrumental in guiding our research and clinical strategy to improve care for women affected by preeclampsia. We are confident that their contributions will play a crucial role in accelerating our progress toward meaningful solutions for mothers and their babies.”\n\n\nThe members of DiaMedica Therapeutics’ Preeclampsia Scientific Advisory Board include:\n\n\nProfessor Vincenzo Berghella\n\n\nProfessor Vincenzo Berghella serves as the Director of Maternal-Fetal Medicine and the Director of the Maternal-Fetal Medicine Fellowship Program at Thomas Jefferson University, as well as a member of the Society for Maternal-Fetal Medicine. Dr. Berghella received his residency at New York Downtown Hospital and completed his fellowship at Thomas Jefferson University Hospital. He is board certified in Obstetrics and Gynecology with a subspecialty in Maternal-Fetal Medicine and holds an impressive portfolio of approximately 700 peer-reviewed publications in renowned journals such as The Lancet, AJOG-MFM, and The Journal of Maternal-Fetal & Neonatal Medicine.\n\n\nProfessor Cathy Cluver\n\n\nProfessor Cathy Cluver, a maternal-fetal medicine specialist, founded and leads the Preeclampsia Research Unit at Tygerberg Hospital, Stellenbosch University, South Africa. Dr. Cluver was awarded the Daubenton Medal for o...